Welcome to our dedicated page for Artivion SEC filings (Ticker: AORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Artivion, Inc. (NYSE: AORT), a medical device company focused on cardiac and vascular surgery and the treatment of aortic diseases. Through these filings, investors can review Artivion’s detailed financial statements, risk disclosures, material agreements and governance information.
Artivion’s periodic reports on Forms 10-K and 10-Q describe its business, which includes aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues, as well as preservation services for cardiac and vascular tissues. These filings outline segment-level information, geographic reach and key risk factors associated with its aortic-focused product portfolio and international operations.
Current reports on Form 8-K document material events such as quarterly financial results, amendments to the company’s credit and guaranty agreement, real estate purchase contracts for manufacturing and office facilities, and executive leadership changes. For example, recent 8-K filings discuss an amendment that extended the maturity of term loan and revolving credit facilities and added a secured delayed draw term loan facility, as well as agreements to purchase properties supporting On-X manufacturing operations in Austin, Texas.
On Stock Titan, Artivion’s SEC filings are updated in near real time as they are posted to EDGAR. AI-powered summaries help explain complex sections of lengthy documents, such as credit agreement amendments, non-GAAP reconciliations, and detailed risk factor discussions. Investors can quickly locate annual reports (Form 10-K), quarterly reports (Form 10-Q), and current reports (Form 8-K), and use AI-generated highlights to understand how new filings may relate to Artivion’s aortic device portfolio, clinical programs, capital structure and corporate strategy.
Artivion, Inc. furnished a press release announcing its financial results for the third quarter ended September 30, 2025. The release is provided under Item 2.02 and is attached as Exhibit 99.1.
The company stated that the information is furnished, not filed, and is not incorporated by reference unless expressly noted. It also included forward‑looking statements subject to the Private Securities Litigation Reform Act safe harbor and directed readers to risk factors in its most recent Form 10‑K and subsequent filings.
BlackRock, Inc. filed Amendment No. 5 to Schedule 13G reporting beneficial ownership of 5,977,264 shares of Artivion, Inc. (AORT) common stock, representing 12.7% of the class as of 09/30/2025.
BlackRock reports sole voting power over 5,912,256 shares and sole dispositive power over 5,977,264 shares, with no shared voting or dispositive power. The filing states the securities were acquired and are held in the ordinary course and not for the purpose of changing or influencing control. The interest of iShares Core S&P Small-Cap ETF in Artivion’s common stock is noted as more than five percent of outstanding shares.
Artivion, Inc. entered into two real estate purchase and sale agreements on September 26, 2025 to buy facilities in Austin, Texas that support and expand its manufacturing operations. The company agreed to purchase from 1300 East Anderson Lane, Ltd. two office buildings it currently leases, which house its On-X manufacturing operation, for a cash price of $12.05 million, including the underlying land and certain equipment, totaling about 75,000 square feet of mixed-use space.
Artivion also agreed to purchase an adjacent building from Sentinel Austin I, LLC for a cash price of $8.45 million, adding roughly 87,000 square feet to its footprint to accommodate rising capacity needs in the coming years. Each agreement includes a feasibility period—45 days for the 1300 Property and 100 days for the 1200 Property—during which Artivion can decide at its sole discretion not to proceed, with closings expected on or before 30 days after each feasibility period, subject to customary conditions.
Artivion, Inc. entered into a Second Amendment to its Credit and Guaranty Agreement with Ares Capital and other lenders. The amendment extends the maturity of its existing term loans and revolving credit facility by one year to January 18, 2031, lowers the interest rate margins on both facilities, and adds a new $150.0 million secured delayed draw term loan facility.
After the amendment, term loans bear interest at either the base rate plus 3.75% or SOFR plus 4.75%, while revolving borrowings are priced at the base rate plus 2.50% or SOFR plus 3.50%. There are no scheduled principal repayments before final maturity, and Artivion can prepay, though prepayments of term loans (and certain revolver reductions below $30,000,000) before July 18, 2027 incur a 1.00% premium.
Subject to a specified maximum total net leverage ratio and other customary conditions, Artivion may draw on the $150.0 million delayed draw term loan facility until September 12, 2027. The company may use these borrowings for permitted acquisitions (including earnouts), other permitted investments, and capital expenditures.
Marshall S. Stanton, SVP, Clinical & MD Affairs at Artivion, Inc. (AORT), exercised stock options and sold an equal number of shares on 08/27/2025. He exercised a stock option with an $11.03 exercise price to acquire 18,200 shares and simultaneously sold 18,200 shares at a weighted average price of $44.023 per share. Following these transactions, Mr. Stanton beneficially owned 64,200 shares of Artivion common stock.
The option exercised had an original grant with a first exercisable date of 11/08/2023 and a stated vesting schedule of 33 1/3% per year. The filing notes the sale price range was $43.84 to $44.26 and that the reporting person can provide a breakdown of shares sold at each price upon request.
Artivion, Inc. (AORT) Form 144 discloses a proposed sale of 18,200 common shares through Morgan Stanley Smith Barney with an aggregate market value of $801,211.32. The shares were acquired and are listed for sale with an approximate sale date of 08/27/2025 following a stock option exercise paid in cash on the same date. The filing shows total shares outstanding of 47,183,658 and lists two prior sales by the same person in June 2025 of 15,000 and 26,132 shares, with gross proceeds of $442,500.00 and $743,129.66 respectively.
Jean F. Holloway, SVP & General Counsel of Artivion, Inc. (AORT), reported transactions on 08/25/2025. She exercised a stock option to acquire 10,000 shares at an exercise price of $11.03 per share and concurrently sold 10,000 shares at $44.37 per share. After these transactions she beneficially owned 172,129 shares. The option exercised relates to a grant with an $11.03 exercise price, originally exercisable beginning 11/08/2023 and expiring 11/08/2029; the option vests 33 1/3% per year starting on the first anniversary of the grant date.
Artivion, Inc. (AORT) Form 144 notice reports proposed sale of 10,000 common shares by an insider via Morgan Stanley Smith Barney LLC, with an aggregate market value of $443,700 and an approximate sale date of 08/25/2025. The form shows those shares were acquired and paid for on 08/25/2025 through a stock option exercise with cash payment. The filing also discloses two recent common-stock sales by JEAN F HOLLOWAY: 23,356 shares sold on 08/12/2025 for $1,004,605.97 and 8,748 shares sold on 05/27/2025 for $253,692.00. The filer affirms no undisclosed material adverse information.
James P. Mackin, President & CEO and director of Artivion, Inc. (AORT), reported a sale of common stock on 08/15/2025. The Form 4 shows he sold 12,500 shares at a weighted average price of $42.319 (prices ranged $42.25 to $42.585). After the transaction he beneficially owned 852,783 shares. The filing is signed 08/19/2025 and the reporting person notes availability of per-price sale details upon request.
Form 144 notice for Artivion, Inc. (AORT) shows a proposed sale of 12,500 common shares through RBC Capital Markets with an aggregate market value of $528,991. The filing lists the approximate sale date as 08/15/2025 and the shares outstanding as 47,183,658. The shares were acquired in open-market purchases: 5,000 shares on 11/13/2019 and 7,500 shares on 11/13/2019 (with payment dated 09/16/2020 for the second lot). The filer reports no sales in the past three months and makes the standard representation about material undisclosed information.